ArticleJournal for immunotherapy of cancer2026
Aging is associated with the outcomes of immune checkpoint blockade in renal cell carcinoma.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging causes gradual and significant declines in immune functions and responses. However, the impact of aging on the immunotherapy outcomes in advanced renal cell carcinoma is largely unknown. Here, we conducted a pooled analysis of individual participant data from two regulatory-approved randomized controlled trials: CheckMate 214 and JAVELIN Renal 101. The overall population (n=1926) included 964 individuals treated with immune checkpoint inhibitors (ICIs) and 962 subjects treated with sunitinib. The optimal age to separate young from old was found to be 60. For young patients, immunotherapy was associated with favorable overall survival (OS; HR=0.70, 95% CI 0.56 to 0.87, p<0.001). For individuals over 60 years old, the OS benefits were marginal (HR=0.82, 95% CI 0.67 to 1.00, p=0.05). Notably, patients with Memorial Sloan Kettering Cancer Center poor risk demonstrated clear benefits from ICIs in this population. Immunotherapy failed to improve OS in patients aged 75 and above (HR=1.05, 95% CI 0.62 to 1.79, p=0.85). Further investigations indicated that young patients exhibited increased infiltration of immune cells, enhanced tumor immunogenicity, and improved immune responses. In summary, the advantage of immunotherapy diminished progressively with age. ICIs were associated with favorable outcomes in young patients. However, for patients over 60 years old, clinicians need to carefully balance efficacy, safety, and patient preferences to deliver individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.